Shorter-Term Dual Antiplatelet Therapy After Receiving Drug-Releasing Stent Does Not Worsen Outcomes
Jamaica Plain, MA -Short-term (3 months) vs. long-term (12 months) dual anti-platelet therapy did not result in poorer outcomes on certain measures (death, heart attack, stroke, and bleeding) for patients with coronary artery disease or low-risk acute coronary syndromes (such as heart attack or unstable angina) treated with drug (zotarolimus)-releasing stents, according to a study published by JAMA. The study is being published early online to coincide with its presentation at the Transcatheter Cardiovascular Therapeutics 25th annual meeting.
“The current recommendation is for at least 12 months of dual antiplatelet therapy [typically aspirin and clopidogrel] after implantation of a drug-eluting stent. However, the optimal duration of dual antiplatelet therapy with specific types of drug-eluting stents remains unknown,” according to background information in the article.
Deepak L. Bhatt, M.D., M.P.H., of the VA Boston Healthcare System, Brigham and Women’s Hospital, and Harvard Medical School, Boston, and colleagues with the OPTIMIZE trial assessed if 3 months of dual antiplatelet therapy was noninferior to (not worse than) 12 months in patients with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with zotarolimus-eluting stents to open narrowed coronary arteries. The study included 3,119 patients in 33 sites in Brazil between April 2010 and March 2012. Clinical follow-up was performed at 1,3,6, and 12 months. Continue>
Page | 1 2
Posted in: Specialties | May 13, 2016